Dr. Gerardo Guillen, the director of research at the Centre for Genetic Engineering and Biotechnology in Havana, Cuba, said a clinical trial is currently being held for a vaccine that is aimed at activating the immune system to combat the Novel coronavirus.
The Cuban researchers were able to make lab technologies available to this research in record time, after the first results were delivered the trials will continue and the results will be analysed.
He was speaking during a recent television interview, and he said that the drug, CIGB 2020, is undergoing trials at the Luis Diaz hospital, it has been given to volunteer patients who are suspected of being carriers of the virus.
Guillen says the drug is both nasally and sublingually administered in order to strengthen these areas to produce encouraging results that have already been observed, in relation to the activation of the innate immune system, which is very important for successfully fighting covid-19.
He also said CIGB 2020 is a drug that is inserted, with another Cuban vaccine that was developed by Finlay Institute, in a research that was debated extensively in contemporary science, it is the development of specific vaccines in order to stimulate innate immunity, which is powered by the new virus.
However, up to Tuesday, there were 766 confirmed COVID-19 cases in Cuba.
The Ministry of Public Health reported that, 599 out of the 766 patients are in stable condition currently.